Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $18.86
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 28, 21 | Bernstein | downgrade | Market Perform | Underperform |
| Sep 9, 21 | Goldman Sachs | upgrade | Neutral | Buy |
| Feb 24, 21 | Bernstein | downgrade | Outperform | Perform |
| Feb 23, 21 | Bernstein | downgrade | Outperform | Market Perform |
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 70.18 | Oscillator | Sell |
| Stochastic %K (14, 3, 3) | 88.70 | Oscillator | Sell |
| Williams %R (14) | -9.85 | Oscillator | Sell |
| MACD (12, 26, 9) | 0.27 (Hist 0.13) | Oscillator | Strong Buy |
| Average Directional Index (14) | 22.19 (+DI 38.7 / -DI 14.3) | Trend | Buy |
| EMA 20 | 18.00 | MA | Strong Buy |
| SMA 20 | 17.79 | MA | Strong Buy |
| EMA 50 | 17.83 | MA | Strong Buy |
| SMA 50 | 17.81 | MA | Strong Buy |
| SMA 200 | 18.68 | MA | Buy |
TTM vs. 5-year historical average (annual ratios)
| Metric | BDRFY | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 19.6x | 31.8x · sector 38.2x | Discount |
| Forward P/E (FY26E) | 22.1x | EPS est. 0.85 | In line |
| Price / Book | 2.0x | 3.1x | Discount |
| Price / Sales | 1.9x | 2.7x | Discount |
| EV / EBITDA | 11.5x | 16.3x | Discount |
| Return on equity | 10.7% | — | Healthy |
| Gross margin | 57.1% | 57.4% | In line |
| Debt / Equity | 0.03 | 0.02 | Conservative |
| Piotroski / Altman Z | 6/9 | Z 4.87 | Safe zone |
Discounted cash flow model
Stock news · updated daily
Beiersdorf Aktiengesellschaft (BDRFY) Q2 2026 Earnings Call Transcript
Beiersdorf Aktiengesellschaft ETR: BEI reported a weaker first half of 2026 as continued pressure at NIVEA outweighed growth in its Derma and Healthcare businesses. The company lowered its full-year outlook for its consumer segment and group sales, while outlining an 18-month plan intended to restore NIVEA to sustainable growth.
Nivea-maker Beiersdorf said conflict in the Middle East is disrupting both sales and deliveries in key Gulf markets, highlighting how geopolitical tensions continue to affect consumer-goods companies operating in the region.
Beiersdorf trimmed its guidance on Monday and now expects an organic sales decline in the low-single digit percentage range this year.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | 0.57 | 0.59 | Beat 4.1% | $5.77B |
| Mar 2, 2026 | 0.43 | 0.42 | Miss -1.9% | $5.40B |
| Jun 30, 2025 | 0.62 | 0.58 | Miss -6.4% | $6.11B |
| Dec 31, 2024 | 0.36 | 0.31 | Miss -15.6% | $4.84B |
| Jun 30, 2024 | 0.60 | 0.55 | Miss -8.3% | $5.56B |
| Feb 29, 2024 | 0.32 | 0.28 | Miss -11.3% | $4.88B |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
SEC EDGAR filings · last 12 months
Proxy statement (DEF 14A) disclosures